Unknown

Dataset Information

0

Anti-angiogenic therapy for ovarian cancer.

ABSTRACT: Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).

SUBMITTER: Garcia Garcia Y 

PROVIDER: S-EPMC7573465 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Anti-angiogenic therapy for ovarian cancer.

García García Yolanda Y   Marín Alcalá Maria M   Martínez Vila Clara C  

EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] 20200822

Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuv  ...[more]

Similar Datasets

Unknown Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.
| S-EPMC3660799 | biostudies-literature
Unknown Anti-angiogenic agents in ovarian cancer: past, present, and future.
| S-EPMC6283356 | biostudies-literature
Unknown Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.
| S-EPMC4656750 | biostudies-literature
Unknown Tumor angiogenesis and anti-angiogenic gene therapy for cancer.
| S-EPMC6019900 | biostudies-other
Unknown Optimization of Ultrasound-mediated Anti-angiogenic Cancer Gene Therapy.
| S-EPMC4817934 | biostudies-other
Unknown Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.
| S-EPMC5795993 | biostudies-literature
Unknown Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.
| S-EPMC8131502 | biostudies-literature
Unknown Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
| S-EPMC5979390 | biostudies-other
Unknown Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
| S-EPMC4476738 | biostudies-literature
Unknown Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.
| S-EPMC8032732 | biostudies-literature